echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Eli Lilly's Lyumjev U.S. label expands continuous subcutaneous insulin infusion drug delivery via insulin pump

    Eli Lilly's Lyumjev U.S. label expands continuous subcutaneous insulin infusion drug delivery via insulin pump

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Eli Lilly recently announced that the US Food and Drug Administration (FDA) has approved the rapid-acting insulin product Lyumjev® (insulin lispro-aabc injection) 100 units/ml label extension to include: through an insulin pump Continuous subcutaneous insulin infusion (CSII) is administered to improve blood glucose control in adults with type 1 and type 2 diabetes


    Lyumjev is a new insulin lispro preparation designed to accelerate the absorption of insulin into the blood and reduce A1C levels.


    This approval is based on the results of the PRONTO-PUMP-2 study


    Lyumjev is available in the United States and several global markets, including Japan and the European Union, where the product is also approved for use in insulin pumps


    Note: The original text has been deleted

    Original source: FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.